BREAST CANCER

The phase III PALOMA-2 trial has shown a significant improvement in progression-free survival (PFS) for the frontline combination of palbociclib (Ibrance) and letrozole compared letrozole alone for patients with ER-positive, HER2-negative advanced or metastatic breast cancer.

The breast cancer guidelines in the United States need to be fixed, which can only be accomplished by those on the frontlines. We need oncologists to chime into the discussion.

Following a series of meetings with the FDA, Puma Biotechnology announced that it plans to delay the submission of a new drug application (NDA) until mid-2016 for neratinib.

Triple Negative Breast Cancer with Andrew Seidman, MD and Joyce O'Shaughnessy, MD

ER+/HER2-Breast Cancer with Adam Brufsky, MD, PhD and Kimberly Blackwell, MD